REPRODUCTIVE ENDOCRINOLOGY
|
|
- Ariel Preston
- 5 years ago
- Views:
Transcription
1 REPRODUCTIVE ENDOCRINOLOGY FERTILITY AND STERILITY VOL. 76, NO. 2, AUGUST 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection Olav Istre, M.D., Ph.D., a and Birgitta Trolle, M.D. b Department of Obstetrics and Gynecology, Central Hospital of Hedmark County, Hamar, Norway Received July 3, 2000; revised and accepted February 12, Supported by Leiras Oy, Turku, Finland. Presented at the XV World Congress of Gynecology and Obstetrics, Washington, DC, September 3 8, Reprint requests: Olav Istre, M.D., Ph.D., Department of Obstetrics and Gynecology, Ullevaal Hospital, University of Oslo, N-0407 Oslo, Norway (FAX: ; E- mail:oistre@c2i.net). a Current address: Department of Obstetrics and Gynecology, Ullevaal Hospital, University of Oslo, Oslo, Norway. b Current address: Department of Obstetrics and Gynecology, Holstebro Central Hospital, Holstebro, Denmark /01/$20.00 PII S (01) Objective: Treatment of menorrhagia with levonorgestrel intrauterine system (LNG IUS) and transcervical resection. Design: An open, therapeutic, randomized study. Setting: Central county hospital specializing in hysteroscopy. Patient(s): Two parallel groups of 30 subjects each. Intervention(s): Thirty patients had a LNG IUS inserted within the first 7 days of menses; 29 patients underwent endometrial resection. Main Outcome Measure(s): A 12-month follow-up of menstrual blood loss and adverse events were evaluated. Result(s): LNG IUS group: 13 patients reported one or more pelvic adverse events, bleeding disorders (n 6), abdominal pain (n 4), breast tenderness (n 3), headache, acne (n 2), and mood changes (n 1). Six patients discontinued treatment because of irregular bleeding (n 3), pain (n 2), and acne (n 1). In both groups, general feeling of genital health increased with Visual Analogue Scale score. Nine patients reported adverse events. This included pelvic pain indicating inflammation (n 4), bleeding (n 3), vaginitis (n 1), and ulceration (n 1). Treatment success at 12 months was achieved in 20 (67%) of the 30 patients in the LNG IUS group and in 26 (90%) of the 29 patients in the transcervical resection group. Adverse events were more often reported in the LNG IUS group. Conclusion(s): Both treatments effectively reduced the menstrual blood loss. Furthermore, the LNG IUS treatment is reversible and has no operative hazards. (Fertil Steril 2001;76: by American Society for Reproductive Medicine.) Key Words: Levonorgestrel intrauterine system, transcervical endometrial resection, menorrhaghia, hysteroscopy The levonorgestrel intrauterine system (LNG IUS, Mirena) is one of the most effective contraceptive methods available, as well as the hormonal contraceptive with the lowest hormonal dose (1). In addition, the LNG IUS significantly reduces menstrual blood loss. The reduction has been reported to exceed 80% in women with confirmed menorrhagia (2). Because the contraceptive effect of the IUS lasts for 5 years, it would seem to offer a simple long-term therapy for menorrhagia and alleviate the need for surgical treatment in a significant number of cases. In recent years, transcervical endometrial resection (TCRE) has become a valid alternative to hysterectomy in the treatment of uterine bleeding disorders. In experienced hands, there are few complications, and promising clinical results have been reported (3). But the operation requires hospitalization, and it is not a suitable technique for women who want to preserve their fertility (4). Some of the concerns connected to the treatment of menorrhagia with the LNG IUS have been the incidence of side effects. The most common complaints resulting in discontinuation of therapy are irregular bleeding and hormonal side effects, such as breast tension, mood changes, and acne (5). The aim of this randomized study was to compare the effect of surgical and hormonal treatment of menorrhagia and the incidence and adverse events. 304
2 MATERIALS AND METHODS The local Institutional Review Board and the Norwegian Medicines Control Authority approved the study after changes in patient information. The Norwegian Medicines Control Authority was to be informed expeditiously of all protocol amendments and all serious unexpected adverse reactions. The patients were recruited from the outpatient clinic, and informed consent was obtained from all women. The study was designed as an open, therapeutic, randomized, comparative study with an LNG IUS group and a TCRE group, each including 30 patients. The patients were assigned to one of the groups in order of their enrollment. Randomizations were done with random permuted blocks (blocks of six subjects). Their general practitioner had referred the women after failed attempts at conservative medical treatment in 40% of the women. The therapy included sequential progestagen and tranexamic acid tablets for 6 months in most of these patients. The other 60% of the patients refused conservative surgery or entered the study directly without previous medication. The waiting list for surgery in the hospital was 6 months or more. Uterine bleeding was quantified by the semiquantitative pictorial blood loss assessment score (PBAC), completed by all subjects over a screening period of 2 months before enrollment (6). The score is recorded on a chart on which the patient registers the number of sanitary pads or tampons used each day, the degree of soiling on each pad or tampon, the number and size of clots passed, and episodes of flooding. A monthly score of 75 on this chart, corresponding to a blood loss of 60 ml, was regarded as excessive bleeding. All tampons and towels used by the patients through the study were Ob Fleur and Saba Normal from Saba.Moelnlycke. All women were premenopausal (serum FSH level of 30 IU/L and 17- E 2 level of 0.2 nanomol/l). Inclusion criteria also included age between 30 and 49 years, a regular uterine cavity 10 cm in length as measured by ultrasound, and no wish for further pregnancy. The evaluation of the uterus was done with transvaginal ultrasound; when the ultrasound findings were in doubt, saline infusion ultrasongraphy or hysteroscopy of the cavity was performed to exclude intrauterine pathology. Exclusion criteria were breast feeding, presence of subserous myoma of 40 mm, current or recent pelvic inflammatory disease, abnormal Papanicolau smear, known endometriosis, breast cancer, a previous history of deep venous thrombosis, thromboembolism or liver disease, and hormone therapy during the last 3 months preceding the study. An endometrial biopsy was performed in all cases. No pretreatment to suppress the endometrium was given. The resection was performed without simultaneous laparoscopy. The cervical canal was dilated to Hegar 11 and a Stortz rigid resectoscope (Ch. 26, model SL; Stortz, Tuttlingen, Germany) equipped with a Hopkins B 30 optic (Stortz) was passed into the uterine cavity. Glycine 1.5% (Baxter, Thetgord, UK) was infused for irrigation. A mixed diathermal current of 120 W (80% cutting/20% coagulation) supplied by a Valleylab Force 2 diathermia unit was routinely used for resection of both fibroids and endometrium. For haemostasis, coagulation current of 80 W was applied. In addition to the PBAC form, all patients also kept a bleeding diary during the screening period. The purpose of this was to register menstrual pain and use of analgesics. All patients also completed a Visual Analogue Scale (VAS) form regarding climacteric symptoms and general feeling of genital health. Pain was registered as number of days that the patient felt mild, moderate, or severe pain. The patients were followed at the outpatient clinic with visits scheduled at 6 weeks, 6 months, and 12 months after the operation or the insertion of the IUD. At all visits, the bleeding diaries and PBAC chart for the preceding months were collected. The patients had a breast and gynecological examination, and their weight and blood pressure was controlled. Any adverse events, defined as new symptoms occurring after treatment, were recorded and classified as local (in the urogenital area) or generalized. Concomitant treatment was recorded, and FSH and E 2 levels were analyzed. Climacteric symptoms were recorded on the VAS scale. No additional treatment for menorrhagia was allowed during the study period. In the TCRE group, only barrier methods were allowed if contraception was needed, and in case the patient could not accept this, a tubal occlusion was performed. Treatment success was defined as a PBAC score of 75 at 12 months. Treatment failure was defined as a PBAC score of 75, resurgery for any reason in the TCRE group, and removal of the intrauterine device in the LNG IUS group. Statistics For the analyses of numerical efficacy and demography variable, the ANOVA or repeated measures ANOVA was used. The continuous variables were tested with two-sample t test or Wilcoxon rank sum test. Categorical variables were tested with Fisher s exact test. The time effect within treatment group was tested with Freedman s test in both groups separately. The level of significance was set at P.05. The data program used was SAS (SAS Institute Inc., Cary, NC). RESULTS LNG IUS Group No complications occurred during the insertions of the IUSs. Dilatation of the cervix was needed in two cases. FERTILITY & STERILITY 305
3 TABLE 1 Pictorial blood loss assessment chart score. Group Visit Mean (SD) Minimum Maximum LNG IUS Baseline 420 (352) 88 1, mo 42 (99) TCRE Baseline 404 (480) 81 2, mo 7 (15) 0 61 Thirteen patients reported one or more local pelvic adverse events, most frequently bleeding disorders (n 6) but also pelvic pain and vaginal discharge. Ten patients reported generalized symptoms, including abdominal pain (n 4), breast tenderness (n 3), headache (n 2), acne (n 2), and mood changes (n 1). Six patients discontinued treatment during the follow-up period: three because of irregular or prolonged bleeding or spotting for 6 months after insertion, two because of pain, and one because of acne and greasy skin. Twenty (83%) of the 24 patients still keeping the LNG IUS after 12 months had a significant reduction in monthly blood loss (MBL; from 420 to 42) measured with PBAC (Table 1), and treatment success was thus achieved in 67% of patients treated. The 6 patients who discontinued treatment underwent a successful endometrial resection, and during the follow-up period of 1 year, none of these patients underwent additional treatment. As indicated in Figure 1, the median VAS score for sleeping problems decreased from baseline to 12-month follow-up, and the overall feeling of genital health increased (P.004). There was no other significant change in climacteric or general symptoms after 12 months of treatment (Fig. 2) and no significant change in serum E 2 level during the study period. Weight and blood pressure did not change. TCRE Group One patient regretted her consent after randomization because she had recently gotten engaged and was considering a pregnancy. Transcervical endometrial resection was thus performed in 29 patients, and all operations were uneventful. Two patients were excluded when analysis of the data was performed because they did not meet the inclusion criteria: one because of PBAC score of 75, the other, because all baseline results were obtained 365 days earlier. Nine patients reported one or more local pelvic adverse FIGURE 1 Median values for VAS (mm). Open bars, baseline for LNG IUS; hatched bars, 12-month follow-up for LNG IUS; filled bars, baseline TCRE; shaded bars, 12-month follow-up for TCRE. 306 Istre and Trolle Treatment of menorrhagia Vol. 76, No. 2, August 2001
4 FIGURE 2 Median values for VAS (mm). Abd abdomen. Open bars, baseline for LNG IUS; hatched bars, 12-month follow-up for LNG IUS; filled bars, baseline TCRE; shaded bars, 12-month follow-up for TCRE. events: pelvic pain and local tenderness indicating inflammation (n 4), bleeding (n 3), vaginitis (n 1), and genital ulceration (n 1). One patient reported abdominal pain, and a total of nine single complaints were recorded. Two patients had a repeat TCRE: one because of pelvic pain and one because of hematometra. This treatment was successful, with no recurrence of symptoms during the study follow-up. Twenty-five (93%) of the 27 patients had a significant reduction of monthly blood loss 12 months after the operation, and average monthly blood loss was reduced from 378 to 7 ml. The median VAS score for sleeping problems also decreased in this group, and the general feeling of genital health increased significantly (P.001). There was no other significant change in climacteric or general symptom or serum E 2. Weight and blood pressure remained stable. Comparison of Groups There was no difference between the groups with regard to baseline variables (Table 2). Blood Loss Treatment success at 12 months was achieved in 20 (67%) of the 30 patients in the LNG IUS group and in 26 (90%) of the patients in the TCRE group. The difference is statistically significant (P.005). There were more frequent reports of adverse events in the LNG IUS group (P.045). Menstrual Pain The number of pain days each month was recorded during the follow-up. A total of 17 patients in the LNG IUS group and 19 in the TCRE group reported mild pain, but there was a significant reduction in pain over time in both groups (P.001 and P.012, respectively). When the number of pain days was compared separately at each of the periods, there was no difference between the groups. TABLE 2 Demographic data by treatment group. Variable LNG IUS TCRE P Age (y) 41.4 (3.8) 41.9 (3.8) 0.63 Sound measure in mm, mean (SD) 7.5 (1.1) 7.7 (1.1) 0.37 Parity (median) 2 (0 5) 2 (1 5) 0.46 Length cycle (d) 28 (21 35) 28 (21 31) 0.39 Duration flow 6.5 (4 10) 7 (4 21) 0.17 FERTILITY & STERILITY 307
5 Climacteric Symptoms The results of the VAS assessment of climacteric symptoms at baseline and 12 months are presented in Figure 2. The median VAS score for sleeping problems decreased in the LNG IUS group and increased in the TCRE group, and this difference reached statistical significance (P.042). There was no difference between the groups in feeling of genital health. Serum E 2 levels fell in both groups during the study period, but the change was not statistically significant. Serum FSH levels rose slightly in both groups, and there was no difference between the groups. Weight or blood pressure did not change in either group during the follow-up period. DISCUSSION The sample size (n 30 in both groups) required to indicate a 15-mL mean difference in MBL was estimated using standard power technique. The method of assessing the amount of blood lost during periods was evaluated in the study by Highham et al. (6). The visual analogue scale is a generally accepted and widely used method of measuring subjective symptoms. There was a dramatic decrease in blood loss in both groups, although this was more pronounced in the TCRE group, as described elsewhere (7). Levonorgestrel administered locally has a profound effect on the endometrium, which becomes atrophic and inactive. This method of treatment has the major advantage of reversibility, in contrast to the methods involving resection or destruction, and it is easier to apply than the surgical methods requiring hysteroscopy. However, the TCRE represents the method of choice in patients with fibroids, at least in the near future (3). But in the absence of fibroids, the LNG IUS is an important alternative to oral medication and surgical methods (1, 2). In the VAS assessment of subjective symptoms and in the bleeding diaries, there was no difference between the groups, except that sleeping problems slightly increased in the TCRE group and decreased in the LNG IUS group. Menstrual pain decreased over time in both groups. This is in concordance with results of other studies examining the effect of local treatment of the endometrium on menstrual pain (8). There is evidence to suggest that hysterectomy may adversely affect the function of conserved ovaries (9). In a retrospective study, this did not seem to be the case after TCRE (10), but it is difficult to eliminate all sources of bias in a retrospective study. In our study, serum FSH tended to increase in both groups, which is not surprising in women approaching the menopause. Two patients in the TCRE group and one in the LNG IUS group had serum FSH levels of 30 IU/L at 6 or 12 months after the inclusion. There was no significant differences between the groups with regard to gonadotropin levels during the follow up period, so if TCRE has an adverse effect on ovarian function, the same seems to be the case for the LNG IUS. One of the most important differences between the two treatment methods is the reversibility of the LNG IUS, which is easily removed, and the nonreversibility of the TCRE. If the subjects in the TCRE group suffered intolerable side effects of the operation, the only possible treatment was a new operation, such as re-tcre or hysterectomy. This can probably explain part of the difference in dropout rate between the groups. Also, the women may have found the hormonal adverse events, such as breast tension, mood changes, and acne, unacceptable. In this study, there were six reports of these symptoms. The hormonal symptoms are most common at the beginning of the treatment, and their incidence is low, probably because of a low steroidal dose (11). The low systemic hormonal impact of the LNG IUS was also demonstrated by the fact that we could not find any difference in body weight between the groups at the 12- month examination. The adverse events found in the present study, such as abdominal pain, acne, and spotting, have also been demonstrated by others (12). In general, the noncontraceptive benefits of the LNG IUS are substantial and far outweigh the negative effects, which are usually mild and transient in nature and can often be managed satisfactorily by counseling (13, 14). A better understanding of these effects, both beneficial and harmful, should lead to more effective patient counseling. This, in turn, should improve user quality of life, minimize unnecessary removals, and maximize continuation of use. The results found in the present study imply that the LNG IUS might primarily treat 60% 70% of patients now scheduled for operative procedures. The result of this study has clearly demonstrated that both LNG IUS and TCRE clearly reduce menstrual blood loss. Although TCRE seems to be even more effective in reducing MBL than LNG IUS, TCRE is an invasive procedure needing operative equipment and theatre. The LNG IUS in the treatment of menorrhagia can be carried out in the outpatient department. This is in line with other studies that found that 64% of 28 women scheduled for hysterectomy due to bleeding problems could cancel their decision to undergo hysterectomy, compared with 14% in the control group (15). Another aspect is the reversibility of the treatment and potential return of fertility associated with LNG IUS. To conclude, the LNG IUS is a contraceptive that has a dramatic effect in lowering bleeding intensity in menorrhagic patients. It is further characterized by reversibility and may be the first-line treatment in younger women with menorrhagia, and because of its low systemic steroidal dose, the adverse events are mild and few. However, TCRE is even more effective in reducing blood loss but implies use of operation facilities, is irreversible, and often requires a new operation if treatment fails. Overall, the tolerability of both treatments is good. 308 Istre and Trolle Treatment of menorrhagia Vol. 76, No. 2, August 2001
6 References 1. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991;164: Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990;97: Istre O. Transcervical resection of endometrium and fibroids: the outcome of 412 operations performed over 5 years. Acta Obstet Gynecol Scand 1996;75: Scottish Hysteroscopy Group. A Scottish audit of hysteroscopic surgery for menorrhagia: complications and follow up. Br J Obstet Gynaecol 1995;102: Gu SJ, Du MK, Zhang LD, Liu YL, Wang SH, Sivin I. A 5-year evaluation of NORPLANT contraceptive implants in China. Obstet Gynecol 1994;83: Higham JM, O Brian PMS, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990;97: Kittelsen N, Istre O. A randomised study comparing levonorgestrel intra uterine system and trans cervical endometrial resection in the treatment of menorrhaghia; a preliminary report. Gynaecol Endosc 1998;7: O Connor H, Magos A. Endometrial resection for the treatment of menorrhagia. N Engl J Med 1996;335: Siddle N, Sarrel P, Whitehead M. The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil Steril 1987; 47: Dean S, Farquharson RG. Ovarian function following transcervical endometrial resection. Gynaecol Endosc 1995;4: Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copperreleasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49: Chi IC, Farr G. The non-contraceptive effects of the levonorgestrelreleasing intrauterine device. Adv Contracept 1994;10: Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/day and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994;61: Purdie DW, Hay AW, Everett M. Short term effects of SHD 386L and levonorgestrel on bone and mineral metabolism in the postmenopause: a double-blind randomised placebo-controlled trial. Maturitas 1992;14: Chi IC, Farr G. The non-contraceptive effects of the levonorgestrelreleasing intrauterine device. Adv Contracept 1994;10: FERTILITY & STERILITY 309
Product Information. Confidence that lasts
Confidence that lasts What is Mirena? Inhibition of sperm motility and function inside the uterus and the fallopian tubes, preventing fertilization (Videla-Rivero et al. 1987). Section of system Levonorgestrel
More information1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7:
1 2 1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7: 777 85. 3 1. Wu JP et al. Extended use of the intrauterine device: a
More informationHeavy Menstrual Bleeding. Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist
Heavy Menstrual Bleeding Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist Why is HMB so important? 1:20 women aged 30-49 consult their GP with HMB Once referred to gynaecologist, surgical
More informationApplication for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines
Application for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines 1. Summary statement of the proposal for inclusion LNG-IUS is an effective contraceptive;
More informationCOLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS, SINGAPORE 2006
COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS, SINGAPORE 2006 CONSENSUS STATEMENT ON THE MANAGEMENT AND EVALUATION OF MENORRHAGIA (INCLUDING MANAGEMENT OF FIBROIDS) Introduction Menorrhagia is defined as
More informationMenstrual Disorders & Ambulatory Gynaecology
Menstrual Disorders & Ambulatory Gynaecology Mr. Nagui Lewis Aziz M B, CH B, FRCOG Consultant Gynaecologist The Royal Oldham Hospital 01/09/2018 Heavy menstrual bleeding (HMB ) is a common problem responsible
More informationREPRODUCTIVE ENDOCRINOLOGY
REPRODUCTIVE ENDOCRINOLOGY FERTILITY AND STERILITY VOL. 82, NO. 1, JULY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Treatment
More informationCLEAR COVERAGE HYSTERECTOMY CHECKLISTS
CLEAR COVERAGE HYSTERECTOMY CHECKLISTS Click on the link below to access the checklist sheet. Abnormal Uterine Bleeding Adenomyosis Chronic Abdominal or Pelvic Pain Endometriosis Fibroids General Guidelines
More information1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7:
1 2 1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7: 777 85. 3 1. Wu JP et al. Extended use of the intrauterine device: a
More informationZurich Open Repository and Archive
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2008 Partial and complete expulsion of the Multiload 375 IUD and the levonorgestrel-releasing
More informationPrimary Care Gynaecology Guidelines: HEAVY REGULAR MENSTRUAL BLEEDING
Primary Care Guidelines: HEAVY REGULAR MENSTRUAL BLEEDING
More informationOriginal Article ABSTRACT
Original Article Effectiveness and safety of Levonorgestrel Releasing Intrauterine System in treatment of menorrhagia secondary to oral anticoagulations and chronic liver disease Abeera Choudry, Ayesha
More informationREPRODUCTIVE ENDOCRINOLOGY
FERTILITY AND STERILITY VOL. 79, NO. 4, APRIL 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. REPRODUCTIVE ENDOCRINOLOGY
More informationInstruction for the patient
WS 4 Case 3 STI and IUD Your situation Instruction for the patient You are 32 years old, divorced and have one child; you have just started a new relationship You underwent surgical resection of the left
More informationExcessive menstrual blood loss
Ian Chilcott Excessive menstrual blood loss >80mls - That interferes with physical, emotional, social and material quality of life 1 in 20 women aged 30 to 49 years consult their GP each year with menorrhagia
More information1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S.
1 2 1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S. The contraceptive action of all IUDs is mainly in the uterine cavity. The major effect
More informationNon-contraceptive Uses of the Levonorgestrel Intrauterine Device Elena Gates, MD http://www.mirena-us.com/pvs1/pri/whatisframe.html Progestin levels with LNG- IUS Lower plasma levels Mirena 150-200 pg/ml
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of microwave endometrial ablation Introduction This overview has been prepared to assist
More informationInvestigating HMB- an evidence based approach
BSGE Meeting: Contemporary management of heavy menstrual bleeding (HMB) in primary and secondary care: (7 th December 2018, RCOG) Investigating HMB- an evidence based approach T. Justin Clark MB ChB, MD(Hons),
More informationEndometrial Cancer Biopsy of the endometrium Evaluation of women of all ages
Endometrial Cancer Biopsy of the endometrium Evaluation of women of all ages Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health System Ann Arbor, Michigan Cancer of the
More informationRole of diagnostic hysteroscopy in evaluation of abnormal uterine bleeding and its histopathological correlation
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Chaudhari KR et al. Int J Reprod Contracept Obstet Gynecol. 2014 Sep;3(3):666-670 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationLevosert levonorgestrel 20mcg/24hour intrauterine device
Levosert levonorgestrel 20mcg/24hour intrauterine device Verdict: Formulary inclusion: Formulary category: Restrictions: Reason for inclusion: Link to formulary: Link to medicine review summary: Levosert
More informationTreatment of menorrhagia with a novel frameless intrauterine levonorgestrelreleasing drug delivery system: a pilot study
European Journal of Contraception & Reproductive Health Care, 2001;6:93-101 Treatment of menorrhagia with a novel frameless intrauterine levonorgestrelreleasing drug delivery system: a pilot study D. Wildemeersch*,
More informationGayatrri Anipindi *, Vani I. Original Research Article. Abstract
Original Research Article Role of levonorgestrel releasing intrauterine device in management of heavy menstrual bleeding: A safe and effective option for all PALM COEIN variants Gayatrri Anipindi *, Vani
More informationOut Patient Hysteroscopy Unit GUIDELINES
Out Patient Hysteroscopy Unit GUIDELINES 1 AIMS The aim of the menstrual assessment clinic [MAC] (incorporating outpatient hysteroscopy) at Queen Charlotte s and Chelsea Hospital will be to provide a one-stop
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of balloon thermal endometrial ablation (Cavaterm) Introduction This overview has been prepared
More informationA Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis
SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident
More informationStudy design Population Results Strengths Weaknesses Quality
Author Year Tasci, 2008 Chattopdh yay, 2011 Desai, 2012 Study design Population Results Strengths Weaknesses Quality observational Location: Turkey Age range: 32-53 observational Location: India Age range:
More informationNICE guideline Published: 14 March 2018 nice.org.uk/guidance/ng88
Heavy menstrual bleeding: assessment and management NICE guideline Published: 14 March 2018 nice.org.uk/guidance/ng88 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationCarl Gustaf Nilsson, M.D. t:j: Hannu Allonen, M.D. Juan Diaz, M.D.II Tapani Luukkainen, M.D., Ph.D.t
FERTILITY AND STERILITY Copyright 0 1983 The American Fertility Society Vol. 39, No.2, February 1983 Printed in U.8A. Two years' experience with two levonorgestrel-releasing intrauterine devices and one
More informationHeavy menstrual bleeding: assessment and management
Heavy menstrual bleeding: assessment and management NICE guideline Draft for consultation, August 0 This guideline covers assessing and treating heavy menstrual bleeding. It aims to help healthcare professionals
More informationTHE EFFECTIVENESS OF THE MIRENA COIL (LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM) IN MENORRHAGIA
THE EFFECTIVENESS OF THE MIRENA COIL (LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM) IN MENORRHAGIA A West Midlands Development and Evaluation Service Report Authors: Antony Stewart, Carole Cummins, Lisa
More informationbleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the
Studies on the diagnosis of endometria cancer in women with postmenopausal bleeding. Studies naar de diagnostiek va endometriumcarcinoom bij vrouwen m postmenopauzaal bloedverlies. Studies on the diagnosis
More informationWhat s New in Adolescent Contraception?
What s New in Adolescent Contraception? Abby Furukawa, MD Legacy Medical Group Portland Obstetrics and Gynecology April 29, 2017 Objectives Provide an update on contraception options for the adolescent
More informationHealthcare Education Research
Healthcare Education Research Heavy menstrual bleeding: investigation, diagnosis & management An update for health professionals Assessment of heavy menstrual bleeding in primary care Dr Amanda Newman
More informationAbnormal uterine bleeding:
Primary Care Women s Health Forum 16th June 2010 Abnormal uterine bleeding: The University Of Birmingham T Justin Clark MD (Hons), MRCOG Consultant Obstetrician and Gynaecologist Birmingham Women s Hospital
More informationPALM-COEIN: Your AUB Counseling Guide
PALM-COEIN: Your AUB Counseling Guide 10 million+ Treat the cause, not the symptom In the U.S, more than 10 million women between the ages of 35 and 49 are affected by AUB 1 Diagnosis Cause Structural
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Review Article ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com A REVIEW ON INTRAUTERINE DEVICES Boddu Venkata Komali* 1, M. Kalyani
More informationEndometriosis. *Chocolate cyst in the ovary
Endometriosis What is endometriosis? Endometriosis is a common condition in young women. It's chronic, painful, and it often progressively gets worse over the time. *Chocolate cyst in the ovary Normally,
More informationDr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre
Dr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre AUB Outline Terminology Classification/Etiology Assessment Treatment Referral to Gynaecology U c pt 4
More information5/5/2010 FINANCIAL DISCLOSURE. Abnormal Uterine Bleeding. Is This A Problem? About me % of visits to gynecologist
Abnormal Uterine FINANCIAL DISCLOSURE I HAVE NO FINANCIAL INTEREST IN ANY OF THE PRODUCTS MENTIONED IN MY PRESENTATION Bryan K. Rone, M.D. University of Kentucky Obstetrics and Gynecology May 5, 2010 About
More informationArdhanu Kusumanto Oktober Contraception methods for gyne cancer survivors
Ardhanu Kusumanto Oktober 2017 Contraception methods for gyne cancer survivors Background cancer treatment Care of gyn cancer survivor Promotion of sexual, cardiovascular, bone, and brain health management
More informationSubject Index. Cavaterm, endometrial ablation complications 146, 150 contraindications 152 cost analysis compared with hysterectomy
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Abnormal uterine bleeding, see also Adenomyosis, Endometrial cancer, Menorrhagia dilatation and curettage 21, 22, 25 hysteroscopy of premenopausal women anesthesia
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Abnormal uterine bleeding in the perimenopause Perimenopausal menstrual problems are among the most common causes for family practitioner and specialist referral. Often it is due to the hormone changes
More informationCURRENT HORMONAL CONTRACEPTION - LIMITATIONS
CURRENT HORMONAL CONTRACEPTION - LIMITATIONS Oral Contraceptives - Features MERITS Up to 99.9% efficacy if used correctly and consistently Reversible method rapid return of fertility Offer non-contraceptive
More informationJ of Evolution of Med and Dent Sci/ eissn , pissn / Vol. 4/ Issue 73/ Sept 10, 2015 Page 12639
TO STUDY THE EFFECT OF ORMELOXIFENE IN MANAGEMENT OF PERIMENOPAUSAL DYSFUNCTIONAL UTERINE BLEEDING Shagufta Anjum 1, Akanksha Agrawal 2, Shabdika Kulshreshtha 3, Rajrani Sharma 4, Namita 5 HOW TO CITE
More informationFrequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc.
Frequency of menses 24 days (0.5%) to 35 days (0.9%) Age 25, 40% are between 25 and 28 days Age 25-35, 60% are between 25 and 28 days Teens and women over 40 s cycles may be longer apart Duration of menses
More informationFibroid mapping. Haitham Hamoda MD FRCOG Consultant Gynaecologist, Subspecialist in Reproductive Medicine & Surgery King s College Hospital
Fibroid mapping Haitham Hamoda MD FRCOG Consultant Gynaecologist, Subspecialist in Reproductive Medicine & Surgery King s College Hospital Fibroids Common condition >70% of women by onset of menopause.
More informationContraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014
Contraception Tami Allen, RNC OB, MHA Robin Petersen, RN, MSN Perinatal Clinical Nurse Specialist Objectives Discuss the impact of unintended pregnancy in the United States Discuss the risks and benefits
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationWendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa
Wendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa Objectives Distinguish the different types of IUDs Understand the mechanism of action and selection of candidates
More informationPrevention, Diagnosis and Treatment of Gynecologic Cancers
Prevention, Diagnosis and Treatment of Gynecologic Cancers Jubilee Brown MD and Pamela T. Soliman MD, MPH Department of Gynecologic Oncology and Reproductive Medicine University of Texas MD Anderson Cancer
More informationAn Update on the Management of Heavy Menstrual Bleeding
An Update on the Management of Heavy Menstrual Bleeding Sonia WM LAI MBBS, MRCOG SL MOK MBBS SK LAM MBBS, FRCOG Department of Obstetrics and Gynaecology, Kwong Wah Hospital, 25 Waterloo Road, Kowloon,
More informationGynecologic Decision Making Based on Sonographic Findings
Gynecologic Decision Making Based on Sonographic Findings Mindy Goldman, MD Department of Obstetrics & Gynecology & Vickie A. Feldstein, MD Department of Radiology University of California, San Francisco
More informationNot all roads point to hysterectomy: treatment options for fibroids
Not all roads point to hysterectomy: treatment options for fibroids MAUREEN KOHI, MD DEPARTMENT OF RADIOLOGY JEANNETTE LAGER, MD DEPARTMENT OF OBSTETRICS, GYNECOLOGY AND REPRODUCTIVE SCIENCES A lady, recently
More informationCorrelation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding
DOI 10.1007/s13224-014-0627-z ORIGINAL ARTICLE Correlation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding Singh Pushpa Dwivedi Pooja Mendiratta Shweta
More informationMEDICAL POLICY SUBJECT: ENDOMETRIAL ABLATION
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationFDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system)
FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system) Mirena does not protect against HIV infection (AIDS) and other sexually transmitted infections
More informationCervical Cancer - Suspected
Cervical Cancer - Suspected Presentation for patients Asymptomatic presentation Symptomatic presentation History and examination Consider differential diagnoses RED FLAG! Cervix appears normal after examination
More informationMedical Management of Fibroids Esmya. Dr Paula Briggs Consultant in Sexual and Reproductive Health
Medical Management of Fibroids Esmya Dr Paula Briggs Consultant in Sexual and Reproductive Health Treatment options for Uterine Fibroids ESMYA Selective Uterine Artery Embolisation Fibroid ablation (hysteroscopic
More informationDiagnostic Features and Therapeutic Consequences of Hysteroscopy in Women with Abnormal Uterine Bleeding and Abortion
American Journal of Applied Sciences 9 (1): 13-17, 2012 ISSN 1546-9239 2012 Science Publications Diagnostic Features and Therapeutic Consequences of Hysteroscopy in Women with Abnormal Uterine Bleeding
More informationAbnormal Uterine Bleeding Case Studies
Case Study 1 Abnormal Uterine Bleeding Case Studies Abigail, a 24 year old female, presents to your office complaining that her menstrual cycles have become a problem. They are now lasting 6 7 days instead
More informationHysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation
SCIENTIFIC PAPER Hysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation O. Shawki, MD, A. Peters, DO, S. Abraham-Hebert,
More informationHormonal Contraception: Asian View. Hormonal Contraception: Asian View: focused on Chinese View. Prof.Dr.Xiangyan Ruan, MD.PhD
Asian View Prof.Dr.Xiangyan Ruan, MD.PhD Beijing Obstetrics & Gynecology Hospital, Capital Medical University (China) WHO Collaborative Centre - Director of Dept. of Gynecological Endocrinology & & - Fertility
More informationA Comparative Study between the Side Effects of Copper Intrauterine Device in Women with Non-scarred and Scarred Uterus
Iraqi JMS Published by Al-Nahrain College of Medicine ISSN 161-659 Email: Iraqi_jms_alnahrain@yahoo.com http://www. colmed-nahrain.edu.iq/ A Comparative Study between the Side Effects of Copper Intrauterine
More informationEndometrial Ablation. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Endometrial Ablation Page: 1 of 10 Last Review Status/Date: December 2012 Endometrial Ablation
More informationYour visit to the Outpatient Hysteroscopy Clinic
Your visit to the Outpatient Hysteroscopy Clinic Department of Gynaecology Patient Information What What is the is an Outpatient outpatient Cystoscopy hysteroscopy? Clinic? An outpatient hysteroscopy means
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationHysteroscopic polypectomy in 240 premenopausal and postmenopausal women
Hysteroscopic polypectomy in 240 premenopausal and postmenopausal women Sangchai Preutthipan, M.D., and Yongyoth Herabutya, F.R.C.O.G. Department of Obstetrics and Gynaecology, Faculty of Medicine, Ramathibodi
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of laparoscopic laser myomectomy Introduction This overview has been prepared to assist
More informationENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA. Study Patients
ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA HUGH O CONNOR, M.R.C.O.G., AND ADAM MAGOS, M.D. ABSTRACT Background Endometrial resection is
More informationEndometriosis. What you need to know. 139 Dumaresq Street Campbelltown Phone Fax
Endometriosis What you need to know 139 Dumaresq Street Campbelltown Phone 4628 5292 Fax 4628 0349 www.nureva.com.au September 2015 What is Endometriosis? Endometriosis is a condition whereby the lining
More informationGLOBAL ENDOMETRIAL ABLATION TECHNOLOGY
GLOBAL ENDOMETRIAL ABLATION TECHNOLOGY Training: Part 1 Anatomy and Physiology Female Anatomy Normal Uterus Female Anatomy Normal Uterus Female Anatomy Uterine Positions Abnormal Uterus Retroflexed Normal
More informationMENSTRUAL PATTERNS AND WOMEN'S ATTITUDES FOLLOWING STERILIZATION BY FA LOPE RINGS*
FERTILITY AND STERILITY Copyright 1979 The American Fertility Society Vol. 31, No.6, June 1979 Printed in U.s.A. MENSTRUAL PATTERNS AND WOMEN'S ATTITUDES FOLLOWING STERILIZATION BY FA LOPE RINGS* LIDIA
More informationlevonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer
levonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer 6 March 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationContraception and gynecological pathologies
1 Contraception and gynecological pathologies 18 years old, 2 CMI normal First menstruation at 14 years old Irregular (every 2/3 months), painful + She does not need contraception She is worried about
More informationHysterectomy. What is a hysterectomy? Why is hysterectomy done? Are there alternatives to hysterectomy?
301.681.3400 OBGYNCWC.COM What is a hysterectomy? Hysterectomy Hysterectomy is surgery to remove the uterus. It is a very common type of surgery for women in the United States. Removing your uterus means
More informationFirst-generation endometrial ablation revisited: retrospective outcome study a series of 218 patients with premenopausal dysfunctional bleeding
Gynecol Surg (2015) 12:291 297 DOI 10.1007/s10397-015-0902-8 ORIGINAL ARTICLE First-generation endometrial ablation revisited: retrospective outcome study a series of 218 patients with premenopausal dysfunctional
More informationDysmenorrhoea Gynaecology د.شيماءعبداالميرالجميلي. Aetiology of secondary dysmenorrhea
30-11-2014 Gynaecology Dysmenorrhoea د.شيماءعبداالميرالجميلي Dysmenorrhoea is defined as painful menstruation. It is experienced by 45 95 per cent of women of reproductive age.primary Spasmodic Dysmenorrhea
More informationCurrent approaches to managing heavy menstrual bleeding
Drug review Heavy menstrual bleeding Current approaches to managing heavy menstrual bleeding Jasmine Tay BM BS, Shruti Mohan MRCOG and Jenny Higham FRCOG SPL The choice of drug treatment for heavy menstrual
More informationQuestion Bank III - BHMS
Question Bank III - BHMS Sub:- Ob/Gy -Paper-II 1. Give the definition of Puberty. 2. Enumerate five important physical changes evident during puberty. 3. Write down the vaginal changes during puberty.
More informationChapter 4. Hysteroscopic morcellator for removal of intrauterine polyps and myomas: a randomised controlled study among residents in training
Chapter 4 Hysteroscopic morcellator for removal of intrauterine polyps and myomas: a randomised controlled study among residents in training Heleen van Dongen Mark Hans Emanuel Ron Wolterbeek J. Baptist
More informationMenorrhagia Update. Simon Edmonds Middlemore Hospital Ascot Central Women s Clinic Auckland
Menorrhagia Update Simon Edmonds Middlemore Hospital Ascot Central Women s Clinic Auckland What is it? Subjective Excessive blood loss at time of menstruation flooding heavy clots Objective > 80mls volume
More informationReview of IUCD Complications: Lessons from CAT. Dr FG Mhlanga CAT Meeting 24 September 2016
Review of IUCD Complications: Lessons from CAT Dr FG Mhlanga CAT Meeting 24 September 2016 INTRODUCTION The intrauterine device (IUD) is a reliable long term reversible, cost-effective,easy to use and
More informationSaid Saleh. Department of Obstetrics and Gynecology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
ARC Journal of Gynecology and Obstetrics Volume 1, Issue 2, 2016, PP 7-12 ISSN No. (Online) 2456-0561 http://dx.doi.org/10.20431/2456-0561.0102003 www.arcjournals.org Efficacy and Acceptability of two
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years
More informationPredicting Intracavitary Lesions Based on Stringent Histologic Criteria to Diagnose Endometrial Polyps
Predicting Intracavitary Lesions Based on Stringent Histologic Criteria to Diagnose Endometrial Polyps Amin A. Ramzan, MD 1 ; Paulette Mhawech-Fauceglia, MD 2 ; Brian Kay, MD 2 ; Teodulo Meneses, MD 2
More informationTopics. Periods Menopause & HRT Contraception Vulva problems
Girls stuff Topics Periods Menopause & HRT Contraception Vulva problems Menorrhagia Excessive menstrual loss occurring with regular or irregular cycles Ovulatory Anovulatory Usual blood loss 30-40ml per
More informationUterine-Sparing Treatment Options for Symptomatic Uterine Fibroids
Uterine-Sparing Treatment Options for Symptomatic Uterine Fibroids Developed in collaboration Learning Objective Upon completion, participants should be able to: Review uterine-sparing fibroid therapies
More informationENDOMETRIAL ABLATION: TRENDS AND CHALLENGES IN 2017
ENDOMETRIAL ABLATION: TRENDS AND CHALLENGES IN 2017 Philippe Laberge MD FRCSC ACGE Professor Obstetrics and Gynecology Laval University Quebec, Canada Disclosures I have used products or done clinical
More informationPalm Beach Obstetrics & Gynecology, PA
Palm Beach Obstetrics & Gynecology, PA 4671 S. Congress Avenue, Lake Worth, FL 33461 561.434.0111 4631 N. Congress Avenue, Suite 102, West Palm Beach, FL 33407 Endometriosis The lining of the uterus is
More informationWHAT ARE CONTRACEPTIVES?
CONTRACEPTION WHAT ARE CONTRACEPTIVES? Methods used to prevent fertilization *Also referred to as birth control methods With contraceptives, it is important to look at what works for you and your body.
More informationIntrauterine delivery of progestogen in the peri- and postmenopausal women. Outline of the presentation. Levonorgestrel releasing IUS - Mirena
QuickTime ja Valokuva - JPEG pakkauksen purkuohjelma tarvitaan elokuvan katselemiseen. Intrauterine delivery of progestogen in the peri- and postmenopausal women ESHRE Campus meeting 6.-7.10.2008 Oskari
More informationBursting Pelvic Inflammatory Disease.
www.infertiltysolutionsng.info/blog Disclaimer The information in this book is provided for educational purposes only and is not intended to treat, diagnose or prevent any disease. The information in this
More informationContraceptive case studies. Dr Christine Roke National Medical Advisor Family Planning June 2015
Contraceptive case studies Dr Christine Roke National Medical Advisor Family Planning June 2015 Case 1 Mary is a 47 year old who has come in for a routine cervical smear. She asks when her Multiload IUD
More informationWelcome to Mirena. The Mirena Handbook: A Personal Guide to Your New Mirena. mirena.com. Mirena is the #1 prescribed IUD * in the U.S.
Mirena is the #1 prescribed IUD * in the U.S. Welcome to Mirena The Mirena Handbook: A Personal Guide to Your New Mirena *Intrauterine Device Supported by 2015-2016 SHS data INDICATIONS FOR MIRENA Mirena
More informationINFERTILITY CAUSES. Basic evaluation of the female
INFERTILITY Infertility is the inability to conceive after 12 months of unprotected intercourse. There are multiple causes of infertility and a systematic way to evaluate the condition. Let s look at some
More informationMultipurpose Intravaginal Ring: Tenofovir / Levonorgestrel
MTN Annual Meeting Bethesda, MD March 17, 2015 Multipurpose Intravaginal Ring: Tenofovir / Levonorgestrel Christine Mauck, MD, MPH Why develop a multipurpose ring? Providing drug in a ring is likely to
More information